Sanofi and Translate Bio have started a phase-I clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza, the companies said on Tuesday.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at risk, such as older adults and younger children, the companies added.
